Observational Study
Copyright ©The Author(s) 2022.
World J Diabetes. Jul 15, 2022; 13(7): 543-552
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.543
Table 1 Baseline characteristics of the study cohort
Variable
Total
Elevated FMN1
Nonelevated FMN2
P value
Patients, n (%)14647 (68)99 (32)
Gender, n (%)0.319
Male72 (49)26 (36)46 (64)
Female74 (51)21 (28)53 (72)
Age (yr)49 (39-55)53 (43-58)47 (35-53)0.008
Diabetes mellitus, n (%)17 (12)14 (82)3 (18)0.000
Hypertension, n (%)18 (12)8 (44)10 (56)0.023
Respiratory failure, n (%)12 (8)6 (50)6 (50)0.291
Corticosteroid therapy, n (%)30 (21)5 (17)25 (83)0.041
WBC [(4.0 × 109/L)-(10.0 × 109/L)]4.64 (3.63-5.82)5.06 (3.85-6.45)4.58 (3.45-5.40)0.067
CRP (< 5 mg/L)7.30 (5.0-25.60)6.80 (5.0-34.90)7.80 (5.0-23.60)0.320
PNI47.80 (44.26-50.58)49.55 (46.05-50.95)47.05 (44.05-49.55)0.061
ALT (0-55 U/L)20.50 (14.0-29.0)22.00 (15.0-31.0)19.00 (13.0-28.0)0.138
AST (0-55 U/L)23.00 (18.0-31.0)25.00 (19.0-32.0)22.00 (18.0-30.0)0.016
SCR (45-84 μmol/L)62 (50-74)64 (55-73)61 (50-75)0.460
TC (3.60-5.70 mmol/L)4.24 ± 0.774.11 ± 0.794.30 ± 0.760.176
TG (0.60-1.70 mmol/L)1.16 (0.86-1.69)1.22 (0.88-1.77)1.14 (0.86-1.66)0.239
HDL-C (1.09-2.27 mmol/L)0.95 (0.80-1.16)0.92 (0.76-1.16)0.98 (0.83-1.16)0.314
LDL-C (1.30-3.37 mmol/L)2.30 (1.94-2.91)2.22 (1.90-2.78)2.32 (1.98-2.92)0.242
Reinfection case, n (%)11 (7.5)8 (73)3 (17)0.008
1Upper third of fructosamine levels.
2Lower two-thirds of fructosamine levels.
Data are presented as the mean (SD) for normally distributed data and median (interquartile range) for non-normal distributed data. PNI = serum albumin (g/L) + 5 × lymphocyte count (× 109/L). P value was calculated using one-sample Kolmogorov-Smirnov test or t-test. WBC: White blood cell count; FMN: Fructosamine; CRP: C-reactive protein; PNI: Prognostic nutritional index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; SCR: Serum creatinine; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol.